| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |



* From the Department of Anesthesiology and Perioperative Medicine, Brigham & Womens Hospital, Harvard Medical School, Boston, Massachusetts, USA; and
the Department of Anesthesiology and Intensive Care, University of Perugia, Perugia Italy.
Address correspondence to: Dr. Carlo Pancaro, Department of Anesthesiology and Perioperative Medicine, Brigham and Womens Hospital, Harvard Medical School, 75 Francis Street, 02115 Boston, MA, USA. E-mail: carlopancaro{at}hotmail.com
Purpose: The incidence and duration of apnea during sevoflurane anesthesia have not been fully characterized. We hypothesized that sevoflurane at slowly increasing concentrations reduces incidence and shortens the duration of apnea compared to administration of a highly concentrated anesthetic mixture.
Methods: 131 women were randomly assigned to receive 35% oxygen in air and sevoflurane at: incremental concentrations of 1%, from 1% to 8% (group 18%, n = 42); decremental-incremental concentrations of 2%, from 8% to 4% and then from 4% to 8% (group 848%, n = 36); or fixed concentrations of 8% for induction of anesthesia (group 8%, n = 53). A blinded investigator observed whether and for how long patients stopped breathing.
Results: All groups reached 2.5 minimum alveolar concentration of end-tidal sevoflurane. Although apnea was observed in all groups, it was more frequent in the 8% group than in 1 to 8% (68% vs 21%, P < 0.05) or 8 to 4 to 8% groups (68% vs 20%, P < 0.05). Duration of apnea was also more pronounced in the 8% group than in 1 to 8% and 8 to 4 to 8% groups ( 58 ± 25 s vs 32 ± 18 sec, P < 0.05 and vs 35 ± 16 sec, P < 0.05, respectively).
Conclusions: Sevoflurane induces apnea more frequently and for longer duration at a fixed high concentration compared to incremental or decremental-incremental concentrations. Decremental-incremental concentrations offer the additional advantage of a speed of induction similar to that elicited by the 8% concentration.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |